Skip to content
$35M Series C Fuels Octave’s Commercial Momentum in Precision Neurology –
Read the Release
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
ECTRIMS 2025
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
ECTRIMS 2025
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
Contact Us
Get In Touch
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
ECTRIMS 2025
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
ECTRIMS 2025
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
Get In Touch
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
ECTRIMS 2025
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
ECTRIMS 2025
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
Real-World Evidence of Tysabri (Natalizumab) Dose Interval Trends in People with Multiple Sclerosis from Administrative Claims Data
March 31, 2023
in
By
Ryan Delduca
Comment
No Comments
Click here
